Reach - non-regulatory announcement
17th May 2022
AGM secures exclusive distribution agreement with Indian partner, Imkemex
International collaboration expands the reach of AGM's graphene products across the Asian chemical market
Applied Graphene Materials (LSE: AGM), the producer of specialty graphene nanoplatelet dispersions, is excited to announce that it has signed an exclusive distribution agreement with Imkemex (Headquartered
Originally formed by ICI India in 1965, Imkemex is now a growing, independent provider of distribution services for overseas chemical companies. The new agreement will see the two organisations collaborate on local opportunities for the application of AGM's proprietary Genable graphene dispersion technology and facilitate wider engagement with new and existing customers within the Indian market.
In addition to its own commercial activity in the
Adrian Potts, AGM CEO commented:
"It is a great pleasure to be able to welcome Imkemex into AGM's growing sales network as a technically-capable, commercially-astute distribution partner for our Genable brand in
Saumendra Tripathy, Managing Director, Imkemex Marketing, commented:
"We at Imkemex are delighted to be AGM's partner of choice for
END
For further information, please contact:
Applied Graphene Materials +44 (0) 1642 438 214
Adrian Potts, Chief Executive Officer
David Blain, Chief Financial Officer
Singer Capital Markets +44 (0) 207 496 3000
Peter Steel / Amanda Gray
Allenby Capital Limited +44 (0) 203 328 5656
Nick Athanas / Liz Kirchner (Corporate Finance)
Matt Butlin / Kelly Gardiner (Sales and Corporate Broking)
Hudson Sandler +44 (0) 207 796 4133
Nick Lyon / Emily Dillon
Notes to Editors
Applied Graphene Materials - For the last decade, AGM has been at the forefront of harnessing the possibilities of graphene. Founded originally by Professor Karl Coleman, the Group has grown from an academic idea from Durham University to a world leader in the development and application of graphene nanoplatelet dispersions for customers in the coatings, composites and functional materials sectors.
The Group utilises its proprietary bottom-up manufacturing process to produce high purity graphene nanoplatelets. Its expertise in dispersion chemistry enables AGM to create optimised, stable and easy to handle dispersions that customers use in real-world industrial products. AGM's unique approach enables industries to fully realise the potential of graphene in a simple, safe and easy to formulate way.
AGM, based at the Wilton Centre on Teesside, was admitted to AIM in November 2013, raising
https://www.appliedgraphenematerials.com/
Imkemex - Originally formed by ICI India in 1965, a management buyout in 1993 saw Imkemex becoming an established, independent provider of distribution, indent and sourcing services for overseas chemical companies. Imkemex operates through multiple offices and storage facilities, ideally located to service the Indian chemical industry and has a sales and customer interaction team of over 20. Imkemex now has a customer base that extends across India with sales to all segments of the industry.
About Reach announcements
This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.